Companies aim to provide new treatments for inflammatory conditions
News
New therapy hope for prostate cancer patients
CR-discovered NXP800 shows promise in clinical trials
NICE recommends olaparib for BRCA-mutated breast cancer treatment
Groundbreaking approval provides new hope for patients in England and Wales
Cambridge Cognition highlights positive Cantab results
New FDA-approved schizophrenia treatment shows promise in clinical trials
Angelini Ventures co-leads Series A financing in Neumirna Therapeutics
Investment to support RNA therapeutics for epilepsy and neurological disorders
Novartis gene therapy set to enhance SMA treatment
OAV101 IT expands potential for type II SMA patients
Merck unveils new cyber-physical trust platform at CES 2025
M-Trust set to improve product safety and counterfeiting solutions
New prostate cancer test cuts biopsies by 50% in US
EpiSwitch PSE shows promise in reducing unnecessary procedures
Amgen’s lung cancer treatment gets conditional approval
IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer
NHS Confederation welcomes social care commission announcement
Government announces independent commission on social care
FDA approves Sequana Medical’s Alfapump for ascites treatment
FDA gives green light to innovative device for liver conditions
EC approves Rybrevant with Lazcluze for advanced lung cancer
New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC
UK regulator warns against buying weight-loss medicines without prescription
MHRA urges caution over illegal medicines from beauty salons and social media
MindMed begins phase 3 study of MM120 for anxiety disorder
First patient dosed in landmark trial for GAD treatment
German cancer centre treats first patient with Elekta Evo
New CT-guided radiotherapy system offers personalised cancer treatment
